concanavalin-a and Glycosuria

Topics: Adult; Blood Glucose; Concanavalin A; Diabetes Mellitus; Female; Glycosuria; Humans; Insulin; Islets of Langerhans; Lymphocyte Activation; Lymphokines; Male; Suppressor Factors, Immunologic

Approximately 50% of DBA/2j male mice infected with EMC-M develop glycosuria with suppressed immune responsiveness to the mitogens PHA, Con A and PWM. The greatest degree of suppression was noted with Con A treated cultures. In vivo treatment with Levamisole, a known T cell stimulant, especially increased the response to Con A but exacerbated the diabetogenic state as reflected by increased occurrence of glycosuria. Virus infected mice, given anti-lymphocyte serum (ALS), showed marked amelioration of the diabetic syndrome. Indomethacin, a non-steroidal anti-inflammatory agent as well as a prostaglandin-synthetase inhibitor, partially reversed the in vitro splenic cell suppression of infected animals.

Topics: Animals; Antilymphocyte Serum; Concanavalin A; Diabetes Mellitus, Experimental; Encephalomyocarditis virus; Enterovirus Infections; Genetic Variation; Glycosuria; Immunosuppression Therapy; Indomethacin; Levamisole; Male; Mice; Mice, Inbred DBA; Phytohemagglutinins; Pokeweed Mitogens

Topics: Aging; Animals; Blood Glucose; Concanavalin A; Diabetes Mellitus, Experimental; Female; Glycosuria; Hyperglycemia; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Pancreas; Rats; Tissue Preservation; Transplantation, Isogeneic